| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2018-10-26 | Shire (UK - USA) | Takeda Pharmaceutical (Japan) | $ 62 billion | Gastroinstestinal diseases - Neurosciences - Rare diseases - Genetic diseases - Immunological diseases |
| 2018-10-18 | Endocyte (USA - IN) | Novartis (Switzerland) | $ 2.1 billion | Cancer - Oncology |
| 2018-10-09 | Vector Neurosciences (UK) | MeiraGTx (USA - NY) | Neurodegenerative diseases - CNS diseases | |
| 2018-10-01 | Sanofi’s inhalation contract manufacturing business | Recipharm (Sweden) | undisclosed | Technology - Services |
| 2018-09-26 | Syntimmune (USA - MA) | Alexion Pharmaceuticals (USA -MA) | up to $1.2 billion | Autoimmune diseases |
| 2018-09-20 | Celenex | Amicus Therapeutics (USA - NJ) | $100 million in an upfront cash payment and up to $15 million in development milestones and $262 million in BLA/MAA submission and approval milestones | Gene Therapy - Rare diseases - CNS diseases |
| 2018-09-14 | Bonti (USA - CA) | Allergan (Ireland) | $195 million and additional potential commercial milestone payments, subject to certain adjustments and other customary closing conditions | aesthetic medicine |
| 2018-09-13 | Viratherapeutics (Austria) | Boehringer Ingelheim (Germany) | €210 million | Cancer - Oncology |
| 2018-09-06 | Advanced Bioprocessing Business from BectonDickinson (USA - NJ) | Thermo Fisher Scientific (USA - MA) | Technology - Services | |
| 2018-09-06 | sanaplasma AG (Switzerland) | Shire (UK - USA) | ||
| 2018-08-31 | Shire's oncology business (UK-USA) | Servier (France) | $2.4 billion (€1.94 billion) | |
| 2018-08-31 | Galderma R&D site in Sophia-Antipolis - Nestlé Skin Health (Switzerland) | Nuvisan (Germany) | CRO - analytical services | |
| 2018-07-24 | Zavante Therapeutics (USA - CA) | Nabriva Therapeutics (Ireland) | up to $ 97.5 million | Infectious diseases |
| 2018-07-23 | TxCell (France) | Sangamo Therapeutics (USA - CA) | € 72 million | Cell therapy - CAR-T - Immunological diseases |
| 2018-07-19 | Agilis Biotherapeutics (USA - MA) | PTC Therapeutics (USA - NJ) | up to $260 million and success-based milestones | Rare diseases - CNS Diseases - Gene therapy |
| 2018-06-16 | Interactive Biosoftware (Frane) | Sophia Genetics (France - Switzerland) | undisclosed | |
| 2018-05-15 | Avexis (USA - IL) | Novartis (Switzerland) | $ 8.7 billion | Gene therapy - Neurodegenerative diseases - CNS diseases |
| 2018-05-14 | AurKa Pharma (Canada) | Eli Lilly (USA - IN) | up to $575 million | Cancer - Oncology |
| 2018-05-10 | ARMO BioSciences (USA - CA) | Eli Lilly (USA - IN) | $1.6 billion | Cancer - Oncology |
| 2018-03-16 | Prexton Therapeutics (Switzerland) | Lundbeck (Denmark) | up to € 905 million | CNS diseases - Neurodegenerative diseases |
